Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

AMGEN (AMGN) stock in plain English

Free brief · no signupStart here
AMGNPublished Nov 14, 2026
AMGEN Inc
Healthcare · Drug Manufacturers - General
Manufactures and sells biologic therapies for oncology, heart disease, inflammation, and rare disorders.
Assets:
Manufacturing networkOperates major biologic production plants in Puerto Rico, Rhode Island, and Ohio.
Global workforceEmploys approximately 27,000 workers worldwide across clinical development and manufacturing.
Commercial portfolioSells seventeen medicines that each generate over one billion dollars in annual sales.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

63
OPS ScoreOperating finances
Latest quote
-1.14%$438.82
$237.36B
25.5×
$38.98B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 14, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was AMGN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does AMGEN (AMGN) do?

AMGEN Inc (AMGN) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Manufactures and sells biologic therapies for oncology, heart disease, inflammation, and rare disorders. It discovers, manufactures, and distributes biologics and complex medicines through proprietary cell-culture processes. It is worth $237.36B on the market and sold $38.98B over the last year.

Market cap
$237.36B
P/E ratio
25.5×
Annual sales
$38.98B
Sector
Healthcare
Industry
Drug Manufacturers - General
Brief updated
Nov 14, 2026

Brands and businesses behind AMGN

  • Prolia: A prescription bone density injection that generates sales from patients treating postmenopausal osteoporosis.
  • Enbrel: An injectable biologic treatment that generates revenue through prescriptions for rheumatoid arthritis and plaque psoriasis.
  • Repatha: A self-injected cholesterol medicine that generates revenue by lowering low-density lipoprotein levels in cardiovascular patients.
  • Otezla: An oral pill that produces revenue by treating plaque psoriasis and psoriatic arthritis in adult patients.
  • Xgeva: An injectable prescription drug that earns revenue by preventing serious bone fractures in patients with cancer.
  • Tepezza: An infused biologic medicine that generates revenue by treating thyroid eye disease symptoms like bulging eyes.

AMGN’s flags, in plain English

Each flag is a number from AMGEN’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.

Wide Gross Margin

Gross margin of 74% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Earns Its Keep

Earns 78.4% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.

Fat Margins

Profit margin of 24.1%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Debt Is Driving

Heavy debt, 376% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about AMGN

How big is AMGEN?

AMGEN’s market cap is $237.36B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $38.98B: what customers paid the company over the last year, before any costs.

What is AMGN’s P/E ratio?

AMGN’s P/E ratio is 25.5×. Investors pay about 25.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with AMGN?

Total debt stands at 42 percent of corporate assets following large debt-financed acquisitions. That is one risk on AMGEN’s card. Its first risk flag is Debt Is Driving, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From AMGEN’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. AMGN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card